Synagis is a humanized antibody inhibitor of the RSV fusion (F) protein. By blocking the interaction of the RSV F protein with the cell membrane, Synagis inhibits viral entry into host cells and also prevents cell-to-cell fusion of infected cells. Passive immunization with Synagis is initiated at the start of the RSV season and requires a total of five monthly doses to maintain protection across the entire period.
LIST OF FIGURES
9 Figure 1: Synagis for respiratory syncytial virus – SWOT analysis
16 Figure 2: Synagis sales for RSV across the US and five major EU markets, 2016/17–2025/26
LIST OF TABLES
6 Table 1: Synagis drug profile
7 Table 2: Synagis Phase III data in RSV
11 Table 3: Recommendations for palivizumab immunization by national authorities, 2018
17 Table 4: Synagis sales for RSV across the US and five major EU markets, by country ($m), 2016/17–2025/26
Datamonitor Healthcare is part of Pharma intelligence
Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726